Literature DB >> 1640738

p53 in chronic myeloid leukemia cell lines.

S Bi1, T Hughes, J Bungey, A Chase, P de Fabritiis, J M Goldman.   

Abstract

Four human chronic myeloid leukemia (CML) cell lines, BV173, K562, KCL-22, and KYO-1, were studied for inactivation of human tumor suppressor gene p53. Southern blotting showed allele deletion in KCL-22 and cytogenetic studies showed a chromosome 17 deletion in KYO-1 but no gross structural abnormalities in the other two lines. Northern blotting showed increased amounts of normal size p53 mRNA in BV-173 and KYO-1, trace amounts in KCL-22, and none in K562. Direct sequencing of p53 cDNA revealed a missense point mutation in KYO-1 and a single base pair deletion consistent with a coding frame shift in KCL-22. Both abnormalities in these myeloid cell lines were located in the highly conserved region of p53. Studies with two monoclonal antibodies showed that the three cell lines with p53 mRNA had readily detectable p53 proteins. In KYO-1 and BV173 cells the p53 protein was located mainly in the nuclei but KCL-22 cells had weak staining in the cytoplasm. Our data support the assumption that inactivation of p53 tumor suppressor function in myeloid blast transformation of CML may result from point mutations or deletions that produce mutant proteins.

Entities:  

Mesh:

Year:  1992        PMID: 1640738

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast.

Authors:  Jana Smardová; Sárka Pavlová; Hana Koukalová
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

2.  Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.

Authors:  X Wei Meng; Brian D Koh; Jin-San Zhang; Karen S Flatten; Paula A Schneider; Daniel D Billadeau; Allan D Hess; B Douglas Smith; Judith E Karp; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

3.  Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells.

Authors:  J Schwaller; H P Koeffler; G Niklaus; P Loetscher; S Nagel; M F Fey; A Tobler
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

4.  Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.

Authors:  Ling Li; Lisheng Wang; Liang Li; Zhiqiang Wang; Yinwei Ho; Tinisha McDonald; Tessa L Holyoake; WenYong Chen; Ravi Bhatia
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

Review 5.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

Review 6.  Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?

Authors:  Vivian M Rumjanek; Raphael S Vidal; Raquel C Maia
Journal:  Biosci Rep       Date:  2013-11-25       Impact factor: 3.840

7.  Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells.

Authors:  Dexin Kong; Shunji Aoki; Yoshihiro Sowa; Toshiyuki Sakai; Motomasa Kobayashi
Journal:  Mar Drugs       Date:  2008-08-26       Impact factor: 5.118

8.  Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation.

Authors:  M G Rizzo; A Zepparoni; B Cristofanelli; R Scardigli; M Crescenzi; G Blandino; S Giuliacci; S Ferrari; S Soddu; A Sacchi
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.